CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis ; volume:23 ; number:1 ; day:29 ; month:8 ; year:2023 ; pages:1-11 ; date:12.2023
BMC cancer ; 23, Heft 1 (29.8.2023), 1-11, 12.2023
- Urheber
-
Ji, Danyang
Luo, Yang
Wang, Jiayu
Chen, Shanshan
Lan, Bo
Ma, Fei
Xu, Binghe
Fan, Ying
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-023-11290-7
- URN
-
urn:nbn:de:101:1-2023110711454311409095
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:00 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ji, Danyang
- Luo, Yang
- Wang, Jiayu
- Chen, Shanshan
- Lan, Bo
- Ma, Fei
- Xu, Binghe
- Fan, Ying
- SpringerLink (Online service)
Ähnliche Objekte (12)
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Development of dual BET/HDAC inhibitors
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
CIK Cells and HDAC Inhibitors in Multiple Myeloma
HDAC inhibitors stimulate viral transcription by multiple mechanisms
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Development of dual BET/HDAC inhibitors
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
CIK Cells and HDAC Inhibitors in Multiple Myeloma
HDAC inhibitors stimulate viral transcription by multiple mechanisms
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Hämatologische Toxizitäten von CDK4/6 Inhibitoren
Development of dual BET/HDAC inhibitors
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)
Entwicklung von Klasse I/IIb Histondeacetylase (HDAC)-inhibitoren und HDAC-PROTACs
Brustkrebstherapie mit CDK4/6-Inhibitoren: Gemeinsamkeiten und Unterschiede
CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
CIK Cells and HDAC Inhibitors in Multiple Myeloma
HDAC inhibitors stimulate viral transcription by multiple mechanisms